ConductScience.org, home

Paper36714853

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus.

Paulowski L and 16 others. PNAS Nexus, 2022. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus. Papers, record 36714853. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36714853

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus.
PubMed
Journal
PNAS Nexus
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.98
iCite
Revised in PubMed
2023-02-02
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Paulowski LLaurahttps://orcid.org/0000-0002-6662-4196
2Beckham KSHKatherine S H
3Johansen MDMatt Dhttps://orcid.org/0000-0001-5553-5270
4Berneking LLaura
5Van NNhi
6Degefu YYonatan
7Staack SSonja
8Sotomayor FVFlor Vasquezhttps://orcid.org/0000-0003-1695-0409
9Asar LLucia
10Rohde HHolger
11Aldridge BBBree Bhttps://orcid.org/0000-0003-2236-1424
12Aepfelbacher MMartin
13Parret AAnnabel
14Wilmanns MMatthiashttps://orcid.org/0000-0002-4643-5435
15Kremer LLaurenthttps://orcid.org/0000-0002-6604-4458
16Combrink KKeith
17Maurer FPFlorian Phttps://orcid.org/0000-0001-8353-5964

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References66

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127300509Immunosuppressive Yersinia Effector YopM Binds DEAD Box Helicase DDX3 to Control Ribosomal S6 Kinase in the Nucleus of Host Cells.PLoS Pathog2016https://conductscience.org/library/papers/27300509PubMed
228396540Rifabutin Is Active against Mycobacterium abscessus Complex.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28396540PubMed
38328779Inactivation of rifampin by Nocardia brasiliensis.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8328779PubMed
426731090Biofilm Formation by Mycobacterium abscessus in a Lung Cavity.Am J Respir Crit Care Med2016https://conductscience.org/library/papers/26731090PubMed
521135185Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.Antimicrob Agents Chemother2011https://conductscience.org/library/papers/21135185PubMed
632651464Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms.J Antibiot (Tokyo)2020https://conductscience.org/library/papers/32651464PubMed
726351633Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China.Biomed Res Int2015https://conductscience.org/library/papers/26351633PubMed
833318008Rifabutin Is Inactivated by Mycobacterium abscessus Arr.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33318008PubMed
918378709Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18378709PubMed
1029026882Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis.Sci Adv2017https://conductscience.org/library/papers/29026882PubMed
1129203492Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29203492PubMed
1220833823Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/20833823PubMed
1330244835Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.Mol Cell2018https://conductscience.org/library/papers/30244835PubMed
1424923585Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis.J Biol Chem2014https://conductscience.org/library/papers/24923585PubMed
1529329759Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.Diagn Microbiol Infect Dis2018https://conductscience.org/library/papers/29329759PubMed
1622290346Mycobacterium abscessus: a new antibiotic nightmare.J Antimicrob Chemother2012https://conductscience.org/library/papers/22290346PubMed
1723998761Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus.Mol Microbiol2013https://conductscience.org/library/papers/23998761PubMed
188785251The clinical pharmacokinetics of rifabutin.Clin Infect Dis1996https://conductscience.org/library/papers/8785251PubMed
1934228543Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/34228543PubMed
2027055097Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions.Nat Protoc2016https://conductscience.org/library/papers/27055097PubMed

See all 66 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42334304Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.J Med Chem2026https://conductscience.org/library/papers/42334304PubMed
41139833A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus.ACS Infect Dis2025https://conductscience.org/library/papers/41139833PubMed
40310456Next-generation rifamycins for the treatment of mycobacterial infections.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40310456PubMed
40148661Alleviation of mycobacterial infection by impairing motility and biofilm formation via natural and synthetic molecules.World J Microbiol Biotechnol2025https://conductscience.org/library/papers/40148661PubMed
39360834Toward better cures for Mycobacterium abscessus lung disease.Clin Microbiol Rev2024https://conductscience.org/library/papers/39360834PubMed
38690364A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing.Front Microbiol2024https://conductscience.org/library/papers/38690364PubMed
38418662Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38418662PubMed
38380095Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches.Front Microbiol2024https://conductscience.org/library/papers/38380095PubMed
37001025Synthesis and Characterization of Phenylalanine Amides Active against Mycobacterium abscessus and Other Mycobacteria.J Med Chem2023https://conductscience.org/library/papers/37001025PubMed
36222275Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.Angew Chem Int Ed Engl2022https://conductscience.org/library/papers/36222275PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36714853

GET https://conductscience.org/api/papers/v1/36714853/references?page=2